Company Overview
Lyell Immunopharma, Inc. operates as a clinical-stage cell therapy company dedicated to developing chimeric antigen receptor (CAR) T-cell product candidates specifically for patients suffering from hematologic malignancies and solid tumors. The company functions within the healthcare sector and the biotechnology industry, positioning itself in a specialized environment focused on advanced immunotherapies rather than traditional small-molecule pharmaceuticals. Its current scale is reflected in a market capitalization of $469.41M and annual revenue of $36,000, while the employee count is listed as N/A. These valuation and revenue figures indicate that the company is a small-cap entity with negligible current revenue generation, suggesting its market position relies heavily on the potential future value of its pipeline assets rather than established commercial sales or significant operational scale at this stage.
Financial Health
The company reported revenue of $36,000 and net income of $-274,448,000 for the trailing twelve months, while EBITDA stood at $-186,746,000. The substantial gap between the minimal revenue of $36,000 and the significant net loss of $274,448,000 reveals a cost structure dominated by research and development expenses and clinical trial costs typical of a pre-commercial biotechnology firm. Free cash flow was reported at $-81,467,128, which indicates that the company is burning through its liquid reserves to fund operations and development activities rather than generating cash from commercial sales. The company holds $247.22M in cash against $50.99M in debt, resulting in a debt-to-equity ratio of 20.55, which suggests a balance sheet that is leveraged relative to equity but maintains significant liquidity buffers. The current ratio is 5.28, indicating strong short-term liquidity and the ability to cover current liabilities with current assets several times over. Return on Equity is -87.0% and Return on Assets is -29.8%, revealing that management effectiveness in generating profit is currently negative due to the lack of commercial revenue and high burn rates. Gross margin stands at 100.0%, operating margin is -1024633.3%, and profit margin is 0.0%, illustrating that while the cost of goods sold is minimal relative to sales, the overall operational and profitability structure is deeply negative due to the pre-revenue status.
Valuation Assessment
The P/E Ratio (TTM) is N/A and the forward P/E is -23.98, implying that the market is pricing the company based on future expectations of earnings that are currently negative or not yet realized. The price-to-book ratio is 1.72, indicating that the market values the company at a 72% premium over its tangible book value, reflecting the intangible value of its intellectual property and pipeline potential. The price-to-sales ratio is an exceptionally high 13039.05, while the EV/EBITDA is -1.46, suggesting that traditional valuation multiples are not applicable and alternative metrics must be used to assess the company's intrinsic value. The 52-week high is $45.00 and the 52-week low is $7.65, meaning the stock has experienced extreme volatility and trading ranges within this specific period. Without a specific current price provided in the facts, the valuation context relies on these extremes to demonstrate the speculative nature of the equity. The beta is -0.15, which is an anomalous value that mathematically implies the stock price moves inversely to the broader market or that the statistical correlation is near zero, suggesting unique risk factors detached from general market movements.
Growth & Income
Revenue growth year-over-year is -45.5% and earnings growth year-over-year is N/A, indicating a contraction in reported revenue figures which is common for companies transitioning from one stage of development to another or adjusting reporting periods. Since the company does not pay dividends, there is no dividend yield and the payout ratio is 0.0%, meaning the company reinvests all available resources into growth initiatives rather than distributing income to shareholders. The absence of a dividend yield and the negative earnings growth profile confirm that the overall growth and income profile is entirely dependent on the successful progression of clinical trials and future commercialization of its lead product candidates. The company's financial strategy focuses on capitalizing on its pipeline assets to achieve profitability rather than generating current cash flow or providing income to investors.